-
Beijing Biostar’s Utidelone Gains FDA Approval for Global Phase II/III Study
•
China’s Beijing Biostar Technologies Ltd (HKG: 2563) announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a global multi-center Phase II/III regulatory study, dubbed BG02-2404. The study will evaluate utidelone in combination with capecitabine and oxaliplatin as a first-line treatment for PD-L1 negative…
-
Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China
•
Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its debut in Hong Kong last month, has entered into a market promotion service agreement with Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company in China. This collaboration will see Baheal provide…
-
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
•
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in China, has successfully completed an initial public offering (IPO) on the Hong Kong Stock Exchange. The company issued 14,588,000 shares at a price of HKD 22 each, raising a total of HKD 320 million (USD…
